

# Product Data Sheet

## Recombinant Human IL-8 (carrier-free)

**Catalog # / Size:** 574202 / 10 µg  
574204 / 25 µg  
574206 / 100 µg  
574208 / 500 µg

**Source:** Human IL-8, amino acids Ser28-Ser99 (Accession # NM\_000584) was expressed in *E. coli*.

**Molecular Mass:** The 72 amino acid recombinant protein has a predicted molecular mass of approximately 8385 Da. The DTT-reduced protein migrates at approximately 8 kD and the non-reduced protein migrates at approximately 10 kD by SDS-PAGE. The N-terminal amino acid is Serine.

**Purity:** >95%, as determined by Coomassie stained SDS-PAGE

**Endotoxin Level:** Less than 0.01 ng per µg cytokine as determined by the LAL method.


**Activity:** Bioactivity was measured by its property to chemoattract human peripheral blood neutrophils in a dose dependent manner. The highest chemotactic activity was detected from 10 to 100 ng/ml.

**Preparation:** 10-100 µg sizes are bottled at 200 µg/mL. 500 µg and larger sizes are bottled at the concentration indicated on the vial.

**Formulation:** 0.22 µm filtered protein solution is in PBS

**Concentration:** The 10, 25, and 100 µg sizes are bottled at a concentration of 200 µg/mL. The 500 µg size is bottled at bulk concentration (see vial or CoA).

**Storage:** Unopened vial can be stored at 4°C for three months, at -20°C for six months, or at -70°C for one year. For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 µg/mL in buffer containing carrier protein such as 1% BSA or HSA or 10% FBS. After dilution, the cytokine can be stored at 4°C for one month or -20°C to -70°C for up to 3 months. **Avoid repeated freeze/thaw cycles.**



Human IL-8 bioactivity

## Applications:

**Applications:** Bioassay

**Description:** IL-8 (CXCL8) was originally recognized as a neutrophil-activating protein on the basis of two in-vitro effects, chemotaxis and the release of granule enzyme. IL-8 is generated as a precursor of 99 amino acids. Once the mature cytokine is secreted, the amino-terminal is processed to yield several biologically active variants. The predominant variant consists of 72 amino acids. IL-8 is one of the ELR (Glu-Leu-Arg) motif-positive CXC-chemokines and shares similarities with angiogenic cytokines.

**Antigen References:**

1. Hess C, *et al.* 2004. *Blood* 104:3463.
2. Emadi S, *et al.* 2005. *Blood* 105:464.
3. Matsuo Y, *et al.* 2009. *Int. J. Cancer* 4:853.
4. Drewniak A, *et al.* 2010. *Blood* 115:4588.



For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.



\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biollegend.com/ordering#license](http://www.biollegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.